Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer

被引:6
|
作者
Maity, Jyotirindra [1 ]
Horibata, Sachi [2 ,3 ,4 ]
Zurcher, Grant [1 ]
Lee, Jung-Min [1 ]
机构
[1] NCI, Womens Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] Michigan State Univ, Precis Hlth Program, E Lansing, MI 48824 USA
[4] Michigan State Univ, Coll Human Med, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA
基金
美国国家卫生研究院;
关键词
ovarian cancer; RecQ helicases; BLM; WRN; RECQL4; novel treatment; WERNER-SYNDROME PROTEIN; ROTHMUND-THOMSON-SYNDROME; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; DNA-DAMAGE; FUNCTIONAL INTERACTION; ATM ACTIVATION; FANCONI-ANEMIA; BLM HELICASE; EXPRESSION;
D O I
10.3390/cancers14051219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
RecQ helicases are essential for DNA replication, recombination, DNA damage repair, and other nucleic acid metabolic pathways required for normal cell growth, survival, and genome stability. More recently, RecQ helicases have been shown to be important for replication fork stabilization, one of the major mechanisms of PARP inhibitor resistance. Cancer cells often have upregulated helicases and depend on these enzymes to repair rapid growth-promoted DNA lesions. Several studies are now evaluating the use of RecQ helicases as potential biomarkers of breast and gynecologic cancers. Furthermore, RecQ helicases have attracted interest as possible targets for cancer treatment. In this review, we discuss the characteristics of RecQ helicases and their interacting partners that may be utilized for effective treatment strategies (as cancers depend on helicases for survival). We also discuss how targeting helicase in combination with DNA repair inhibitors (i.e., PARP and ATR inhibitors) can be used as novel approaches for cancer treatment to increase sensitivity to current treatment to prevent rise of treatment resistance.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Targeting tumor associated pH regulators: Effective therapeutic strategy in ovarian cancer
    Kulshrestha, Arpita
    Katara, Gajendra K.
    Ibrahim, Safaa A.
    Young, Alexandria N.
    Levine, Shayna
    Riehl, Valerie E.
    Bilal, Mahmood
    Gilman-Sachs, Alice
    Beaman, Kenneth
    CANCER RESEARCH, 2019, 79 (13)
  • [22] Targeting ATP Synthase by Bedaquiline as a Therapeutic Strategy to Sensitize Ovarian Cancer to Cisplatin
    Zhu, Hongyan
    Chen, Qitian
    Zhao, Lingling
    Hu, Pengchao
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2023, 75 (04): : 1271 - 1280
  • [23] Wrestling off RAD51: a novel role for RecQ helicases
    Wu, Leonard
    BIOESSAYS, 2008, 30 (04) : 291 - 295
  • [24] Therapeutic Targeting of Glutaminolysis as a Novel Strategy to Combat Cancer Stem Cells
    Kao, Ting-Wan
    Chuang, Yao-Chen
    Lee, Hsin-Lun
    Kuo, Chia-Chun
    Shen, Yao-An
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [25] Exploring targeting potassium channels in cancer: A novel strategy for therapeutic intervention
    Breuer, Eun-Kyoung
    Osipo, Clodia
    Zartman, Jeremiah
    Wells, Claire
    Nishimura, Michael
    Jones, Walter
    Gentile, Saverio
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10)
  • [26] Novel RNA Therapeutic Strategy to Optimize RNA Targeting in Brain Cancer
    Fink, Ryan
    Gawargi, Flobater
    Sine, Laura
    Hintelmann, Thomas
    Hicks, Martin J.
    MOLECULAR THERAPY, 2022, 30 (04) : 280 - 280
  • [27] Targeting GPR89 as a novel therapeutic strategy for breast cancer
    Ferro, R.
    Carroll, A.
    Hickman, O.
    Vlachogiannis, G.
    Trendell, J.
    Krastev, D.
    Pettitt, S.
    Amodeo, V.
    Annunziato, S.
    Jonkers, J.
    Liv, N.
    Pardo, M.
    Roumeliotis, T. I.
    Choudhary, J.
    Natrajan, R.
    Grigoriadis, A.
    Madhusudhan, M. S.
    Haider, S.
    Lord, C. J.
    Tutt, A.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S113 - S113
  • [28] Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancer
    Marczyk, M.
    Gunasekharan, V.
    Wali, V. B.
    Shi, W.
    Patwardhan, G.
    Qing, T.
    Pusztai, L.
    Hatzis, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] Novel therapeutic strategy for prostate cancer treatment by targeting extracellular vesicles
    Urabe, Fumihiko
    Kosaka, Nobuyoshi
    Yamamoto, Yusuke
    Takeshita, Fumitaka
    Kimura, Takahiro
    Egawa, Shin
    Ochiya, Takahiro
    CANCER SCIENCE, 2018, 109 : 1189 - 1189
  • [30] Development of novel therapeutic strategy targeting Histone acetyltransferases for colorectal cancer
    Okinaka, Erika
    Noguchi, Yuki
    Kobayashi, Shino
    Iwai, Shiina
    Shimada, Sae
    Suzuki, Yuta
    Oyama, Mai
    Adachi, Souichi
    Kamikubo, Yasuhiko
    CANCER SCIENCE, 2018, 109 : 1347 - 1347